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A B S T R A C T
Essential thrombocythemia (ET) has been reported to cause acute coronary disease. However, the
efﬁcacy of anti-platelet therapy for ET is unclear since there are individual differences in the platelet
function of ET patients. Here we report a case of a 62-year-old man with ET who was admitted to our
hospital because of acute coronary syndrome. He underwent coronary angioplasty. Dual anti-platelet
therapy with aspirin (81 mg/day) and clopidogrel (75 mg/day) was subsequently initiated. We evaluated
platelet reactivity in P2Y12 reaction units, and subsequently determined anti-platelet drugs and
corresponding doses.
<Learning objective: Essential thrombocythemia (ET) is a myeloproliferative disorder that causes acute
coronary disease. As there are individual differences in the platelet function of patients with ET, the
efﬁcacy of anti-platelet therapy for these patients varies. Evaluation of platelet reactivity using P2Y12
reaction units is useful in determining appropriate anti-platelet drugs and corresponding doses.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Essential thrombocythemia (ET) is a myeloproliferative disor-
der that causes thrombus formation in systemic arteries including
the coronary arteries. A previous study reported that the incidence
of acute coronary events in ET patients was 9.4% [1]. Paradoxically,
ET can cause secondary von Willebrand disease, which is
characterized by excessive bleeding, especially when platelet
count is over 1,000,000–1,500,000/mm3 [2]; however, thrombosis
is more frequent than hemorrhage in patients with ET.
There are individual differences in the platelet function of ET
patients. Furthermore, studies have shown that the efﬁcacy of
clopidogrel has interpatient variability because of genetic factors,
especially in Asian people [3]. Since clopidogrel is a prodrug that
requires metabolism by cytochrome P450 (CYP) enzymes, the* Corresponding author at: Department of Cardiology, Ako City Hospital, 1090,
Nakahiro, Ako-shi, Hyogo 6780232, Japan. Tel.: +81 791 43 3222;
fax: +81 791 43 0351.
E-mail address: kouchiboy@hotmail.com (N. Yoshida).
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1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightefﬁcacy of clopidogrel is affected by CYP genetic variation. Platelet
reactivity to clopidogrel can be measured in P2Y12 reaction units
(PRU) using VerifyNow1 (Accumetrics, San Diego, CA, USA).
There are some reports of acute coronary syndrome (ACS) with
ET, however, there are few reports focused on anti-platelet
therapy. Here we present a case of ET accompanied by ACS with
percutaneous coronary intervention (PCI). We determined the
dose of anti-platelet therapy while evaluating the platelet
reactivity using PRU in order to prevent recurrent thrombosis
and hemorrhage events.
Case report
A 62-year-old man was admitted to our hospital with severe
chest pain. He had been experiencing episodes of chest pain for
three weeks. One evening, severe chest pain occurred and did not
subside until the follow evening, when he visited our hospital. He
was a current smoker and had a previous history of ET treated with
hydroxyurea (500 mg/day) 25 years earlier. He had wild-type JAK2
V617F. He had a family history of coronary artery disease. His vital
signs on admission revealed blood pressure of 156/91 mmHg, as reserved.
Fig. 1.
Right coronary angiography (458 left anterior oblique) and intravascular ultrasound. (A) Severe stenosis without ﬂow limitation. (B) A large amount of thrombus
in the culprit lesion.
Fig. 2.
Time course of platelet count following admission. Thrombocytosis due
to essential thrombocythemia was treated with hydroxyurea. The
shaded area shows platelet count of less than 741,000/mm3. PRU,
P2Y12 reaction units.
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evaluation revealed his platelet count was 1,200,000/
mm3. Electrocardiography showed ST elevation in leads II, III,
and aVF, and ST depression in leads I, aVL, and V2–6. The
transthoracic echocardiogram showed a hypokinesis of wall
motion in the posteroinferior region. These ﬁndings indicated
ACS and therefore oral aspirin (162 mg) was initiated prior to a
coronary angiogram (CAG). The CAG showed 99% stenosis in the
proximal right coronary artery (Fig. 1A). Intravascular ultrasound
(IVUS) showed a large amount of thrombus in the culprit lesion
(Fig. 1B). Aspiration thrombectomy was performed, and white
thrombus was withdrawn. Pre-dilatation and stenting
(3.5 mm  18 mm biolimus-eluting stent) were performed suc-
cessfully with Thrombolysis In Myocardial Infarction grade
3 coronary ﬂow. The maximum creatine kinase level reached
was 382 IU/L. Dual anti-platelet therapy (DAPT) with aspirin
(81 mg/day) and clopidogrel (75 mg/day) was initiated after
300 mg clopidogrel loading. Although the patient’s platelet count
on admission was high (1,200,000/mm3), von Willebrand factor
antigen levels (136%) and ristocetin cofactor activity levels (99%)
were normal. We increased the dose of hydroxyurea to decrease
his platelet count and prevent thrombosis and hemorrhage (Fig. 2).
His genotype of CYP 2C19 was wild-type (CYP2C19*1/*1), namely
extensive metabolizer. PRU measured by VerifyNow1 are only
available when platelet count is less than 741,000/mm3; therefore,
we measured PRU at 35 days after administration when his platelet
count was 557,000/mm3. A PRU value of 5 was obtained by
VerifyNow1. Although the efﬁcacy of clopidogrel was potent, we
decided to continue DAPT with the same drugs at the same doses
because the patient was classiﬁed as high risk for thrombosis due to
age and thromboembolic complication [2]. The patient’s platelet
count decreased to within near normal range, and the PRU value
changed from 5 to 72. We performed follow-up CAG and optical
coherence tomography (OCT) six months after stenting. CAG showed
normal coronary artery and no in-stent restenosis, and OCT images
showed that most of the struts were covered, and that there were
uncovered struts and peri-strut low intensity area (Fig. 3). We
decided to continue DAPT with the same drugs at the same doses for
one year. Seven months have passed since we performed stenting.
There has been no major thrombosis or bleeding event.
Discussion
ET is a myeloproliferative disorder that causes thrombus
formation in systemic arteries including the coronary arteries.Furthermore, ET can cause hemorrhage events because of
secondary von Willebrand disease. Secondary von Willebrand
disease is caused by thrombocytes strongly binding to von
Willebrand factor especially when platelet count is over
1,000,000–1,500,000/mm3 [2]. In Japan, 17.6% of ET patients have
thrombosis, and 4.2% have hemorrhage [4].
In our patient, smoking and a family history of coronary artery
disease were coronary risk factors in addition to ET. Moreover, the
relationship of ET with the JAK2 V617F mutation is prominent. One
study demonstrated that JAK2 V617F was associated with a higher
number of immature platelets in ET patients [5]. This mutation was
not identiﬁed in our case. Because the patient was considered as
being at high risk for thrombotic complications, we reinforced
myelosuppressive therapy using hydroxyurea to prevent throm-
botic complications [2]. The patient had already been treated with
hydroxyurea however, his platelet count was 1,200,000/mm3 on
admission and therefore, we increased the doses of hydroxyurea in
order to decrease his platelet count.
Aspirin (81 mg/day) with clopidogrel (75 mg/day) was initiated
in our patient since it is a standard therapy for the prevention of
stent thrombosis following PCI. Clopidogrel suppresses platelet
aggregation inhibiting P2Y12 receptor. A previous study demon-
strated that the efﬁcacy of clopidogrel differed individually
because there are factors that cause resistance to clopidogrel:
genetic, clinical, and cellular factors [6]. Genetic factors are largely
Fig. 3. Optical coherence tomography image six months after stenting. (A) Covered struts. (B) Uncovered struts. (C) Peri-strut low intensity area.
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into active metabolite by CYP2C19. As the genotype of our patient
was CYP2C19*1/*1, he did not have genetic resistance to
clopidogrel. Clinical factors include factors associated with
inadequate clopidogrel response: compliance, smoking, drug–
drug interactions, diabetes mellitus, and obesity. As our patient
was a smoker, smoking reinforced the efﬁcacy of clopidogrel (PRU
5). After he quitted smoking, PRU of 72 was obtained. There is no
relationship between clopidogrel and hydroxyurea because
hydroxyurea is not metabolized by CYP2C19. He did have diabetes
mellitus and was not obese. Cellular factors include platelet
turnover and CYP activity. In addition, it is important to know
whether thrombocytosis has caused secondary von Willebrand
disease in ET patients. In the case presented here, the patient’s von
Willebrand factor antigen levels and ristocetin cofactor activity
levels were evaluated and determined to be within the normal
range, meaning that he did not suffer from secondary von
Willebrand disease.
We evaluated platelet reactivity using PRU to conﬁrm the
efﬁcacy of clopidogrel objectively and to determine the appropri-
ate doses of clopidogrel. We measured PRU according to
VerifyNow1. The instrument measures platelet-induced aggrega-
tion as an increase in light transmittance and uses a proprietary
algorithm to report values in PRU. Anti-platelet treatment regi-
mens need to be within a range that is not too high or too low in
order to reduce the risk of ischemic and bleeding events. In general,
the therapeutic range of PRU is from 98 to 208 [6]. Previous studies
have shown that clopidogrel poor response did not reduce
cardiovascular death, myocardial infarction, and stent thrombosis
following PCI [7]. One report suggested that all ET patients with
recurrent thrombosis showed a poor response to clopidogrel
[8]. Therefore, we had to conﬁrm the efﬁcacy of clopidogrel to
prevent recurrent thrombosis events.
There are no reports of PRU in patients with thrombocytosis
(platelet count >741,000/mm3); therefore, in the case presented
here, we measured PRU when the patient’s platelet count had
decreased to within 741,000/mm3 using hydroxyurea. PRU values
from 5 to 72 were obtained. Considering that lower PRU values are
associated with hemorrhage risk, there could have been an event of
hemorrhage. However, because the patient was classiﬁed as at
high risk for recurrent thrombosis by age >60 years and had a
history of thrombosis, thrombosis risk was higher than hemor-
rhage risk [5]. As the therapeutic range of PRU may vary accordingto the patient’s phenotype, patients with a high risk of thrombosis
may need high platelet aggregation inhibition [9]. Therefore,
knowing that the patient’s platelet aggregation inhibition levels
were high, we decided to continue DAPT with the same drugs at the
same doses. To date, he has experienced no thrombosis or
hemorrhagic event.
Here we present a case of ACS with ET. Evaluating PRU plays an
important role in determining DAPT after PCI especially in ET since
the optimal range of platelet inhibition differs between patients.
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